The first COVID-19 vaccines, while engender robust humoral responses, have mixed potential for inducing CD8+ T cell responses (Anderson et al., 2020; Ewer et al., 2020; Jackson et al., 2020; Sahin et al., 2020; Zhang et al., 2021). The gene discussed is CD8A; the disease is COVID-19.